SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending following a promising earnings report, which highlighted a substantial new credit facility and several Material Transfer Agreements, notably one focused on oncology. The community is optimistic about the diversification potential of its Matrix-M adjuvant in new therapeutic areas, with discussions also circling around short interest and the strategic influence of major shareholders.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending after delivering stellar earnings and robust guidance, yet the immediate market response has been surprisingly flat, sparking community debate over 'IV crush' and manipulation despite numerous analyst price target upgrades reinforcing its AI and data center dominance.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

Eos Energy Enterprises is experiencing a significant downturn following a substantial earnings and revenue miss, leading to widespread investor frustration and questions about management's credibility, while some observers cautiously eye the sharp pullback as a potential buying opportunity given the broader demand for battery energy storage systems.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals is trending following strong financial results, including profitability, coupled with the FDA approval of ORLADEYO for pediatric use and highly anticipated data for their long-acting navenibart. The community is actively discussing a potential short squeeze and whether the company's achievements will finally attract broader market recognition.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius (CELH) is surging after a strong earnings report exceeded expectations and positive comments from a recent conference revealed significant shelf-space gains for its brands, particularly Alani Nu, and strong international growth potential. While bulls celebrate robust performance and anticipate continued expansion, community discussions also include concerns over the CEO's communication style and speculative theories about a potential PepsiCo buyout.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is trending after reporting strong revenue and customer growth in its latest quarter, with the market increasingly noting its dominance as China's intense coffee price war appears to be easing. The community is weighing rapid store expansion and perceived undervaluation against lingering concerns over profit margins and the ongoing desire for a US market relisting.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is trending following financial results that highlight strong revenue growth and new partnerships, particularly in defense and government sectors, bolstering optimism for its dual-platform technology and commercial potential. Nevertheless, significant operating losses and its valuation continue to spark intense community debate about its long-term viability and pathway to profitability within the evolving quantum computing landscape.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

Despite Briumvi's robust revenue growth and recently published strong long-term efficacy data, TG Therapeutics' stock faces investor frustration due to elevated operating expenses and conservative guidance, leading to calls for management to prioritize shareholder value. The community actively debates the path forward, with discussions centered on the potential for an acquisition and the impact of significant short interest on the stagnant share price.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is trending after reporting strong financial results and a bullish outlook, amplified by its strategic acquisition of SkyWater Technology and a significant defense contract award; this has ignited community discussion, with proponents highlighting its quantum computing leadership while skeptics question its valuation and long-term profitability.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

The Trade Desk (TTD) is seeing intense volatility after its Q4 earnings beat was overshadowed by weaker-than-anticipated Q1 guidance, sparking a major sell-off. While many in the community view the sharp decline as an overreaction and a generational buying opportunity given strong fundamentals and planned share buybacks, others express deep concern over decelerating growth and management's strategy amid competitive pressures in the ad tech sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$AUPH I agree with respect to the patent litigations there is a Rule 16 telephonic conversation scheduled for March 23rd and keep in mind all the 5 litigations have been bundled up into 1 case.  During or after a Rule 16 phone conversation, settlements may typically be made.  With regard to the Tidmarsh litigation, I don&#39;t think it is as huge deterrent as the generic litigations (which can be settled as per above), as BP is better equipped to handle defamation cases.

Joey Sunshine

KnysnaNow

Toni Dewada

Jim Hicks

Ricardo

Derr

ThomasLD

Plumber_123

$AUPH $98.2/12.2 = $8.05 average share price.  They repurchased shares at very low price.
They lowered the bar on the future guidance to ensure they keep beating estimates going forward.
$135M cash flow supports development of two new indications for AUR200.
This company is in BO position for any BP.  The only issues preventing a BO are the patent infringement and lawsuits.

StockTwits for iOS

Aurinia Pharmaceuticals Inc

Pedro

StockTwits Web

 I agree with respect to the patent litigations there is a Rule 16 telephonic conversation scheduled for March 23rd and keep in mind all the 5 litigations have been bundled up into 1 case.  During or after a Rule 16 phone conversation, settlements may typically be made.  With regard to the Tidmarsh litigation, I don't think it is as huge deterrent as the generic litigations (which can be settled as per above), as BP is better equipped to handle defamation cases.

Allways_Do_Your_Own_DD

@US_Bull they talked years ago about cutting a deal and allowing generics in around 2032 ish. Makes sense as 6 or 7 more years of exclusivity and theoretically, their new drug would already hit market. Sales won’t go to zero allowing them in, just need to cut the price.

Joseph Robbins

 they talked years ago about cutting a deal and allowing generics in around 2032 ish. Makes sense as 6 or 7 more years of exclusivity and theoretically, their new drug would already hit market. Sales won’t go to zero allowing them in, just need to cut the price.

Tim Fris

@timfris True but currently they are infringing on our 036&#39; and 991&#39; patents at least here in the US, where our major revenues are from obviously.  With respect to COM patent they can enter anywhere but LN anywhere in the world in Oct. 2027.  Generics cannot affor to take this to a jury trial where they will be found guilty of wilfull infringment and pay heavy damages.  A settlement would be the best solution with a license and future royalties paid to us.

 True but currently they are infringing on our 036' and 991' patents at least here in the US, where our major revenues are from obviously.  With respect to COM patent they can enter anywhere but LN anywhere in the world in Oct. 2027.  Generics cannot affor to take this to a jury trial where they will be found guilty of wilfull infringment and pay heavy damages.  A settlement would be the best solution with a license and future royalties paid to us.